CD80 and nephrotic syndrome: Additionally, B7-1, as a novel biomarker for podocyte damage, was suggested to be a potential therapeutic target for most chronic kidney diseases, and a clinical trial for B7-1 blockade in nephrotic syndrome patients is currently ongoing [24–26].